Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
From - Diagnostic Testing & Emerging Technologies
The number of new cases of metastatic prostate cancer climbed 72 percent from 2004 to 2013, according to a controversial new study published…
From - Diagnostic Testing & Emerging Technologies
Clinically relevant pharmacogenomic findings are seen in single nucleotide polymorphism (SNP) genotyping and exome sequencing data…
From - Diagnostic Testing & Emerging Technologies
Genomic Data Commons (GDC) launched this week as a core component of the National Cancer Moonshot and the President's Precision Medicine Initiative to promote data sharing between cancer researchers and accelerate the pace of…